Table 5. Previous studies on radiotherapy with or without chemotherapy as salvage treatment for patients with postoperative locoregional recurrence of oesophageal squamous cell carcinoma.

Study	n	Treatment (n)	ORR	MST (month)	1 year OS	2 year OS	3 year OS
Raoul, J. L., 199513	31a	RT + CT	65%	<12	47.1%	17.1%	4.3%
Nemoto, K., 200129	33	RT alone (21)	91%	7	33%	15%	12%
		RT + CT (CF) (12)
Shioyama, Y., 200712	82	RT alone (52)	78%	7	/	22%	/
		RT + CT (30)
Nakamura, T., 200811	22	RT + CT	82%	20.3	/	/	26.6%
Lu, J. C., 201028	73	RT alone (42)	76%	9	33.8%	/	0.0%
		CCRT with CF (31)	97%	17	62.5%		10.5%
Maruyama, K., 201127	23	RT + CT	/	13	52%	31%	/
Jingu, K., 201226,16	30	CCRT with three-weekly NF	73.3%	21	60.6%	/	38.4%
Bao, Y., 201214	83	CCRT (3D-CRT)	75.9%	43	/	/	51.8%
Zhang, J., 201230	50	CCRT with four-weekly CF (22)	72.7%	9.8	56%	/	14%
		CCRT with three-weekly TP (28)	71.4%	16.3
Fakhrian, K., 201231	54b	RT alone (18)	/	12	55%	29%	19%
		CCRT (36)
Ma, D. Y., 201424	98	3D-CRT alone (49)	73.5%	19	69.4%	/	28.6%
		CCRT with weekly cisplatin (49)	91.8%	35	85.7%		46.9%
Kobayashi, R., 201415	42c	RT alone (7)	97.6%	24.3	81.2%	51.3%	41.1%
		CCRT with four-weekly regimen (35)
Current study	27	CCRT with weekly CF (14)	70.4%	26	88.9%	60.2%	/
		CCRT with weekly NF (13)

Abbreviations: 3D-CRT = three-dimensional conformal radiotherapy; CCRT = concurrent chemoradiotherapy; CF = cisplatin + 5-FU; CT = chemotherapy; MST = median survival time; NF = nedaplatin + 5-FU; OS = overall survival; ORR = overall response rate; RT = radiotherapy; TP = paclitaxel + cisplatin.

^aIncluding seven patients having distant metastasis with (1 patient) or without locoregional recurrence (6 patients).

^bIncluding 17 patients with adenocarcinoma and eight patients who received definitive radiochemotherapy as initial treatment.

^cIncluding one patient with carcinosarcoma.